ChemicalBook > Product Catalog > API > Antineoplastic agents > Antitumor Adjuvant Drugs > Orelabrutinib
Orelabrutinib
Orelabrutinib Basic information
- Product Name:
- Orelabrutinib
- Synonyms:
-
- :6-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-3-Pyridinecarboxamide
- Orelabrutinib
- ICP-022
- 3-Pyridinecarboxamide, 6-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-
- Orelabrutinib USP/EP/BP
- 6-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide
- Malignancies,Btk,ICP 022,inhibit,antineoplastic,Inhibitor,chronic,small,Bruton tyrosine kinase,lymphocytic leukemia,cell,Orelabrutinib,ICP022
- Orelabrutinib (ICP-022)
- CAS:
- 1655504-04-3
- MF:
- C26H25N3O3
- MW:
- 427.49
- Mol File:
- 1655504-04-3.mol
More
Less
Orelabrutinib Chemical Properties
- Boiling point:
- 646.3±55.0 °C(Predicted)
- Density
- 1.213±0.06 g/cm3(Predicted)
- pka
- 14.80±0.50(Predicted)
More
Less
Orelabrutinib Usage And Synthesis
Description
Orelabrutinib is a small molecule inhibitor of Bruton's tyrosine kinase with potential antineoplastic activity.
Uses
Orelabrutinib has been previously approved to treat patients with relapsed or refractory (R/R) mantle cell lymphoma and R/R chronic lymphocytic leukemia/small lymphocytic lymphoma.
Biological Activity
Orelabrutinib (ICP-022) is a potent, orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
Mechanism of action
Upon administration, orelabrutinib binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK.